Small Amounts of Sub-Visible Aggregates Enhance the Immunogenic Potential of Monoclonal Antibody Therapeutics
- 1.8k Downloads
Determine the effect of minute quantities of sub-visible aggregates on the in vitro immunogenicity of clinically relevant protein therapeutics.
Monoclonal chimeric (rituximab) and humanized (trastuzumab) antibodies were subjected to fine-tuned stress conditions to achieve low levels (<3% of total protein) of sub-visible aggregates. The effect of stimulating human dendritic cells (DC) and CD4+ T cells with the aggregates was measured in vitro using cytokine secretion, proliferation and confocal microscopy.
Due to its intrinsic high clinical immunogenicity, aggregation of rituximab had minimal effects on DC activation and T cell responses compared to monomeric rituximab. However, in the case of trastuzumab (low clinical immunogenicity) small quantities of aggregates led to potent CD4+ T cell proliferation as a result of strong cytokine and co-stimulatory signals derived from DC. Consistent with this, confocal studies showed that stir-stressed rituximab was rapidly internalised and associated with late endosomes of DC.
These data link minute amounts of aggregates with activation of the innate immune response, involving DC, resulting in T cell activation. Thus, when protein therapeutics with little or no clinical immunogenicity, such as trastuzumab, contain minute amounts of sub-visible aggregates, they are associated with significantly increased potential risk of clinical immunogenicity.
KEY WORDSanti-drug antibodies biotherapeutics CD4+ T cell responses humanized antibodies immunogenicity
B cell receptor
Cytometric bead array
Dynamic light scattering
Major histocompatibility complex
Monocyte derived dendritic cell
Follicular helper T cell
Conflict of interest
The authors declare no conflicts of interest.
- 5.Kreuz W, Ettingshausen CE, Zyschka A, Oldenburg J, Saguer IM, Ehrenforth S, et al. Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products. Semin Thromb Hemost. 2002;28(3):285–90.CrossRefPubMedGoogle Scholar
- 17.Herceptin® [package insert] Genentech Inc, San Francisco, USA. http://www.gene.com/download/pdf/herceptin_prescribing.pdf
- 19.Sojka DK, Bruniquel D, Schwartz RH, Singh NJ. IL-2 secretion by CD4+ T cells in vitro is rapid, transient, and influences by TCR-specific competition. J Immuno. 2004;172(10):6136–43.Google Scholar
- 25.Rönnelid J, Tejde A, Mathsson L, Nilsson-Ekdahl K, Nilsson B. Immune complexes from SLE sera induce IL10 production from normal peripheral blood mononuclear cells by an FcgammaRII dependent mechanism: implications for a possible vicious cycle maintaining B cell hyperactivity in SLE. Ann Rheum Dis. 2003;62(1):37–42.CrossRefPubMedCentralPubMedGoogle Scholar
- 40.Brinks V, Weinbuch D, Baker M, Dean Y, Stas P, Kostense S, et al. Preclinical models used for immunogenicity prediction of therapeutic proteins. Pharm Res. 2013;30(7):1719–28.Google Scholar